Indomethacin (Indometacin)
Brand names: Indocid, Indocid-R
Indometacin (indomethacin) is a potent non-steroidal anti-inflammatory drug used in rheumatology for acute gout, ankylosing spondylitis and other inflammatory arthropathies where strong anti-inflammatory and analgesic effect is required.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It non-selectively inhibits cyclo-oxygenase (COX-1 and COX-2), reducing prostaglandin synthesis to produce anti-inflammatory, analgesic and antipyretic effects.
Prescribing in practice
- Gastrointestinal toxicity, including ulceration and bleeding, is a major risk and gastroprotection should be considered, especially in older or higher-risk patients.
- Central nervous system effects such as headache, dizziness and confusion are more prominent than with many other NSAIDs and limit tolerability in the elderly.
- It carries the NSAID cardiovascular and renal cautions and should be avoided or used with care in heart failure, renal impairment and with other nephrotoxic or anticoagulant drugs.
Monitoring
Monitor renal function, blood pressure and for gastrointestinal and CNS adverse effects, particularly in older patients and with prolonged use, as advised in the SPC.
Counselling the patient
- Take with or after food and report black stools, abdominal pain or indigestion.
- Report headache, dizziness or confusion, especially when starting.
- Use the lowest effective dose for the shortest time.
Evidence & guidelines
Long-standing trial and clinical experience supports indometacin's efficacy in acute gout and inflammatory arthritis, with its side-effect profile shaping cautious use.
Reference: ESC Pericarditis Guidelines 2015; BSR Gout Guidelines 2017; NICE NG219 (Gout); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022